Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-Lung01: Izalontamab Brengitecan vs platinum-based chemotherapy in EGFR-mutated NSCLC after EGFR-TKI
jRCT2011260019Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival by BICR (RECIST v1.1). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2011260019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260019.